+91 780-304-0404

Cancer Biomarkers Market

Global Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker and Protein Biomarker), By Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, and Cervical Cancer), by Application (Drug Discovery & Development, Diagnosis, Risk Assessment, and Prognostics), and by Profiling Technology (Omics Technology, Immunoassays, Cytogenetics, and Bioinformatics) Forecast Period (2022-2028)

Published: Jul 2019 | Report Code: OMR2026581 | Category : Biotechnology | Delivery Format: /
Global Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker and The global cancer biomarker market is anticipated to grow at a significant CAGR of 12.4% during the forecast period. Biomarker testing is a method of looking for cancer-related genes, proteins, and other chemicals (also known as biomarkers or tumor markers). It comprises distinct patterns in each person's cancer. Some biomarkers have an impact on the effectiveness of cancer therapy. Thus, due to the increasing prevalence of cancer coupled with the rising awareness related to the usage of biomarkers at various stages of cancer is fuelling the market growth. According to the World Health Organization (WHO), in 2020, cancer is a leading cause of death globally, accounting for nearly 10 million deaths. Another factor that intends to drive the market is the usage of cancer biomarkers in drug discovery and technological development by the key market players. The biomarker development and technological advancement increase the accuracy of the detection of cancer in an individual at an early stage. Similarly, various government and private sectors are investing in the development of cancer biomarkers, which in turn is expected to the market growth.

Impact of COVID-19 Pandemic on Global Cancer Biomarker Market

The COVID-19 pandemic had a significant impact on almost every business and industry. Due to the COVID-19 pandemic, healthcare facilities were facing massive pressure to create a well-coordinated environment where all clinical functions are linked internally and where the organization operates in coordination with other healthcare units. With the rising incidences of COVID-19, several companies increased their focus on the development of drugs or vaccines for COVID-19, showing a negative impact on interventional and other cancer biomarker-related clinical trials, which have been stopped as a result of the COVID-19 virus situation across the world.  For instance, in March 2020, Pfizer paused the recruitment portion of certain global interventional clinical trial studies to avoid adding to the demands on the healthcare system during the peak of the crisis.

Segmental Outlook 

The global cancer biomarker market is segmented based on the biomarker type, cancer type, application, and profiling technology. Based on the biomarker type, the market is segmented into genetic biomarkers and protein biomarkers. Based on, the cancer type, the market is sub-segmented into lung cancer, prostate cancer, breast cancer, colorectal cancer, and cervical cancer. Based on the application, the market is segmented into drug discovery and development, diagnosis, risk assessment, and prognostics. Further, based on profiling technology, the market is sub-segmented into omics technology, immunoassays, cytogenetics, and bioinformatics. The above-mentioned segments can be customized as per the requirements. Based on profiling technology, the omics technology sub-segment is holding a prominent share in the global cancer biomarker market. Omics technology has become a field of intensive research aiming at identifying biomarkers relevant for improved diagnostics and therapeutics.

Global Cancer Biomarker Market Share by Biomarker Type, 2021 (%)

Global Cancer Biomarker Market Share, by Type

The Protein Biomarker Sub-Segment is anticipated to Hold a Prominent Share in the Global Cancer Biomarker Market

Protein Biomarker is estimated to account for a major share in the global cancer biomarker market owing to the advancement in technology such as Mass Spec (MS) technology. In addition, the creation of powerful bioinformatics software, spectral libraries, and peptide databases, are creating new opportunities for developing protein biomarkers for the diagnosis, prognosis of disease, and prediction of response to treatment. Moreover, Protein biomarkers used in effective breast cancer control will be supported by early detection to diagnose and treat breast cancer in its pervasive state before metastasis. Protein biomarkers are mainly used in the diagnosis of breast cancer, which is the second leading cause of cancer-related death among women across the globe.

Regional Outlooks

The global cancer biomarker market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement. Among these, Asia-Pacific has been estimated to have significant growth due to improving biopharmaceutical research centers and a large number of products in the pipeline portfolio. 

Global Cancer Biomarker Market Growth, by Region 2022-2028

Global Cancer Biomarker Market Growth, by Region

The North American Region is Expected to Hold a Prominent Share in the Global Cancer Biomarker Market

North America is expected to hold a prominent share of the market owing to growing cancer biomarkers in the region. Factors that are contributing significantly to the market growth include a rise in several R&D activities coupled with high healthcare expenditure. Moreover, the rising number of cancer patients owing to the changing lifestyle is another major factor driving the growth of the market in the region. According to the WHO, every year almost 400 000 youngsters are diagnosed with cancer. In the US, approximately 89,500 cancer cases were diagnosed in adolescents and young adults (AYAs) aged 15 to 39 years in 2020, with approximately 9,270 cancer fatalities. Hence, personalized medicine tends to treat a person by decreasing the side effects by utilizing therapies and biomarkers for various forms of cancers such as lung, breast, and others that propels the market growth in the region.

Market Players Outlook

The major players serving the growth of the global cancer biomarker market include Abbott Laboratories Inc., Bio-Rad Laboratories, Inc., Danaher Corp., F. Hoffmann-La Roche Ltd., Illumina, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., QIAGEN GmbH, Thermo Fisher Scientific Inc., and many others. The players operating in the market adopt various strategies such as technology development, product launch, merger, and acquisition for gaining a sustainable position in the market that further propels the growth of the market. For instance, in May 2019, QIAGEN GmbH launched an FDA-approved companion diagnostic for PIK3CA biomarkers to improve precision medicine in breast cancer will enhance the company’s position in the market.

The Report Covers

  • Market value data analysis of 2021 and forecast to 2028.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global cancer biomarker market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

1.Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Cancer Biomarker Market
  • Recovery Scenario of Global Cancer Biomarker Market

1.1.Research Methods and Tools

1.2.Market Breakdown

1.2.1.By Segments

1.2.2.By Region

2.Market Overview and Insights

2.1.Scope of the Report

2.2.Analyst Insight & Current Market Trends

2.2.1.Key Findings

2.2.2.Recommendations

2.2.3.Conclusion

3.Competitive Landscape

3.1.Key Company Analysis

3.2. Abbott Laboratories Inc.

3.2.1.Overview

3.2.2.Financial Analysis 

3.2.3.SWOT Analysis

3.2.4.Recent Developments

3.3.F. Hoffmann-La Roche Ltd.

3.3.1.Overview

3.3.2.Financial Analysis 

3.3.3.SWOT Analysis

3.3.4.Recent Developments

3.4. Merck and Co., Inc.

3.4.1.Overview

3.4.2.Financial Analysis 

3.4.3.SWOT Analysis

3.4.4.Recent Developments

3.5.Novartis AG

3.5.1.Overview

3.5.2.Financial Analysis 

3.5.3.SWOT Analysis

3.5.4.Recent Developments

3.6.Key Strategy Analysis

3.7.Impact of COVID-19 on Key Players

4.Market Segmentation

4.1.Global Cancer Biomarker Market by Biomarker Type

4.1.1.Genetic Biomarker

4.1.2.Protein Biomarker      

4.2.Global Cancer Biomarker Market by Cancer Type

4.2.1.Lung Cancer        

4.2.2.Prostate Cancer    

4.2.3.Breast Cancer 

4.2.4.Colorectal Cancer 

4.2.5.Cervical Cancer 

4.2.6.Other        

4.3.Global Cancer Biomarker Market by Application

4.3.1.Drug Discovery and development 

4.3.2.Diagnosis

4.3.3.Risk Assessment

4.3.4.Prognostics

4.4.Global Cancer Biomarker Market by Profiling Technology

4.4.1.Omnic Technology 

4.4.2.Immunoassays 

4.4.3.Cytogenetics 

4.4.4.Bioinformatics

5.Regional Analysis

5.1.North America

5.1.1.United States

5.1.2.Canada

5.2.Europe

5.2.1.UK

5.2.2.Germany

5.2.3.Italy

5.2.4.Spain

5.2.5.France

5.2.6.Rest of Europe 

5.3.Asia-Pacific

5.3.1.China

5.3.2.India

5.3.3.Japan

5.3.4.South Korea

5.3.5.Rest of Asia-Pacific 

5.4.Rest of the World

6.Company Profiles 

6.1.Abcodia Ltd.

6.2.Agendia N.V.

6.3.Agilent Technologies, Inc.

6.4.Astellas Pharma Inc.,

6.5.Becton, Dickson, and Co.

6.6.Biodesix, Inc.

6.7.BioMérieux S.A.

6.8.Bio-Rad Laboratories, Inc.

6.9.Danaher Corp.

6.10.Diazyme Laboratories Inc.

6.11.Hologic, Inc.

6.12.Illumina, Inc.

6.13.Myriad Genetics, Inc.

6.14.NeoGenomics, Inc.

6.15.Pfizer Inc.

6.16.QIAGEN GmbH

6.17.Thermo Fisher Scientific Inc.

1.GLOBAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2021-2028 ($ MILLION)

2.GLOBAL GENETIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

3.GLOBAL PROTEIN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

4.GLOBAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)

5.GLOBAL LUNG CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

6.GLOBAL PROSTATE CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

7.GLOBAL BREAST CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

8.GLOBAL COLORECTAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

9.GLOBAL CERVICAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

10.GLOBAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

11.GLOBAL CANCER BIOMARKER FOR DRUG DISCOVERY AND DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

12.GLOBAL CANCER BIOMARKER FOR DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

13.GLOBAL CANCER BIOMARKER FOR RISK ASSESSMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

14.GLOBAL CANCER BIOMARKER FOR PROGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

15.GLOBAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY PROFILING TECHNOLOGY, 2021-2028 ($ MILLION)

16.GLOBAL OMICS TECHNOLOGY IN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

17.GLOBAL IMMUNOASSAYS IN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

18.GLOBAL CYTOGENETICS IN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

19.GLOBAL BIOINFORMATICS IN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

20.GLOBAL CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)

21.NORTH AMERICAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)

22.NORTH AMERICAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2021-2028 ($ MILLION)

23.NORTH AMERICAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)

24.NORTH AMERICAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

25.NORTH AMERICAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY PROFILING TECHNOLOGY, 2021-2028 ($ MILLION)

26.EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)

27.EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2021-2028 ($ MILLION)

28.EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)

29.EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

30.EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY PROFILING TECHNOLOGY, 2021-2028 ($ MILLION)

31.ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)

32.ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2021-2028 ($ MILLION)

33.ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)

34.ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

35.ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY PROFILING TECHNOLOGY, 2021-2028 ($ MILLION)

36.REST OF THE WORLD CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)

37.REST OF THE WORLD CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2021-2028 ($ MILLION)

38.REST OF THE WORLD CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)

39.REST OF THE WORLD CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

40.REST OF THE WORLD CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY PROFILING TECHNOLOGY, 2021-2028 ($ MILLION)

1.IMPACT OF COVID-19 ON GLOBAL CANCER BIOMARKER MARKET, 2021-2028 ($ MILLION)

2.IMPACT OF COVID-19 ON GLOBAL CANCER BIOMARKER MARKET BY SEGMENT, 2021-2028 ($ MILLION)

3.RECOVERY OF GLOBAL CANCER BIOMARKER MARKET, 2022-2028 (%)

4.GLOBAL CANCER BIOMARKER MARKET SHARE BY BIOMARKER TYPE, 2021 VS 2028 (%)

5.GLOBAL GENETIC CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

6.GLOBAL PROTEIN CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

7.GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE, 2021 VS 2028 (%)

8.GLOBAL LUNG CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

9.GLOBAL PROSTATE CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

10.GLOBAL BREAST CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

11.GLOBAL COLORECTAL CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

12.GLOBAL CERVICAL CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

13.GLOBAL OTHER CANCER BIOMARKER BY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

14.GLOBAL CANCER BIOMARKER MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)

15.GLOBAL CANCER BIOMARKER FOR DRUG DISCOVERY AND DEVELOPMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

16.GLOBAL CANCER BIOMARKER FOR DIAGNOSIS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

17.GLOBAL CANCER BIOMARKER FOR RISK ASSESSMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

18.GLOBAL CANCER BIOMARKER FOR PROGNOSTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

19.GLOBAL CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY, 2021 VS 2028 (%)

20.GLOBAL OMICS TECHNOLOGY IN CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

21.GLOBAL IMMUNOASSAYS IN CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

22.GLOBAL CYTOGENETICS IN CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

23.GLOBAL BIOINFORMATICS IN CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

24.GLOBAL CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

25.US CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

26.CANADA CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

27.UK CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

28.FRANCE CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

29.GERMANY CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

30.ITALY CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

31.SPAIN CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

32.REST OF EUROPE CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

33.INDIA CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

34.CHINA CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

35.JAPAN CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

36.SOUTH KOREA CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

37.REST OF ASIA-PACIFIC CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

38.REST OF THE WORLD CANCER BIOMARKER MARKET SIZE, 2021-2028 ($ MILLION)

Choose License Type
    On Discount

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports